Medicina Interna, Reumatologia, Immunologia, IRCCS San Raffaele
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dagna, Lorenzo
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Active, not recruiting
3
397
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps
Recruiting
3
1700
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
NCT06332183: GWAS and EWAS in Patients With Erdheim-Chester Disease

Recruiting
N/A
300
Europe
Presence of polymorphisms
Augusto Vaglio
Erdheim-Chester Disease
07/24
10/24
AIDA, NCT05200715: AutoInflammatory Disease Alliance Registry

Recruiting
N/A
3500
Europe, US, RoW
No intervention is foreseen by the protocol.
University of Siena
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome
08/23
08/30
COVID-BioB, NCT04318366: COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor

Recruiting
N/A
6000
Europe
Observational Study
Università Vita-Salute San Raffaele
Coronavirus Infections
03/25
03/25

Download Options